血清紫藤凝集素阳性mac-2结合蛋白的治疗变化与慢性乙型肝炎

StephenW

J Med Virol. 2019 Mar 24. doi: 10.1002/jmv.25465. [Epub ahead of print]
On-treatment changes of serum wisteria floribunda agglutinin-positive mac-2 binding protein are associated with the regression of liver fibrosis in chronic hepatitis B patients on interferon α add-on therapy.
Liu T1, Sun Y1, Zhou J1, Yang F2, Zou X2, Wang L1, Wu X1, Chen Y3, Piao H4, Lu L5, Jiang W6, Xu Y7, Feng B8, Nan Y9, Xie W10, Chen G11, Zheng H12, Li H13, Ding H14, Liu H15, Wang T16, Ou X1, Wu S17, Kong Y17, Wang P1, Cong M1, Zhang Y2, You H1, Jia J1.
Author information

1
    Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory of Translational Medicine in Liver Cirrhosis, National Clinical Research Center of Digestive Diseases, Beijing, China.
2
    Key Laboratory of Systems Biomedicine Ministry of Education, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China.
3
    Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
4
    Infectious Department, Affiliated Hospital of Yanbian University, Yanji, China.
5
    Department of Gastroenterology and Hepatology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
6
    Department of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai, China.
7
    Department of Digestive System, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
8
    Hepatology Institute, Peking University People's Hospital, Beijing, China.
9
    Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
10
    Center of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
11
    Second Liver Cirrhosis Diagnosis and Treatment Center, 302 Military Hospital of China, Beijing, China.
12
    Department of Infectious Disease, the Fifth Hospital of Shijiazhuang City, Shijiazhuang, China.
13
    Department of Hepatopancreatobiliary and Splenic Medicine, Affiliated Hospital, Logistics University of People's Armed Police Force, Tianjin, China.
14
    Department of Gastroenterology and Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, China.
15
    Department of Pathology, Beijing Youan Hospital, Capital Medical University, Beijing, China.
16
    Department of Pathology, China-Japan Friendship Hospital, Beijing, China.
17
    Clinical Epidemiology and Evidence-Based Medicine Unit, National Clinical Research Center for Digestive Diseases, Beijing, China.

Abstract

Wisteria floribunda agglutinin-positive Mac-2-binding protein (M2BPGi) has been identified as a predictor for response of interferon α (IFN α) in patients with viral hepatitis. However, whether serum M2BPGi was associated with the regression of liver fibrosis in patients with chronic hepatitis B (CHB) during IFN α add-on therapy is still unknown. CHB patients were treated with entecavir for 26 weeks followed by entecavir plus peglated-IFN α for 52 weeks. Liver biopsies were taken at baseline and treatment week 78. The regression of fibrosis was identified according to Ishak standard or Ishak plus Progressive-Indeterminate-Regressive (P-I-R) standard. Serum M2BPGi and liver function tests were measured at baseline and every 26 weeks of treatment. A total of 72 CHB patients were included in the present study. Serum M2BPGi was correlated with fibrosis and necroinflammation both at baseline and week 78. If Ishak standard was used as reference, only the percent change of M2BPGi at week 52 from week 26 (Δ%M2BPGi26w-52W ) was independently associated with fibrosis regression at treatment week 78, the area under the ROC curve (AUROC) of Δ%M2BPGi26w-52W for predicting fibrosis regression was 0.705. As for Ishak plus P-I-R standard, the AUROC of the predictive model for fibrosis regression (0.896*M2BPGi52W + 0.363*necroinflammation score0w + 2.051*Ishak score0w - 4.489) was 0.888. These data indicated that dynamic changes of serum M2BPGi were associated with fibrosis regression in CHB patients on IFN α add-on therapy. This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.
KEYWORDS:

Chronic hepatitis B; M2BPGi; interferon α; liver fibrosis; regression

PMID:
    30905065
DOI:
    10.1002/jmv.25465

StephenW

J Med Virol。 2019年3月24日doi：10.1002 / jmv.25465。 [印刷前的电子版]
血清紫藤凝集素阳性mac-2结合蛋白的治疗变化与慢性乙型肝炎患者干扰素α附加治疗后肝纤维化的消退有关。
Liu T1，Sun Y1，Zhou J1，Yang F2，Zou X2，Wang L1，Wu X1，Chen Y3，Piao H4，Lu L5，Jiang W6，Xu Y7，Feng B8，Nan Y9，Xie W10，Chen G11，Zheng H12 ，Li H13，Ding H14，Liu H15，Wang T16，Ou X1，Wu S17，Kong Y17，Wang P1，Cong M1，Zhang Y2，You H1，Jia J1。
作者信息

1
    首都医科大学附属北京友谊医院肝病研究中心，北京市肝硬化转化医学重点实验室，国家消化病临床研究中心，北京，中国。
2
    上海交通大学系统生物医学教育部重点实验室，上海系统生物医学中心，上海。
3
    南方医科大学南方医院感染科，广东广州
4
    延边大学附属医院感染科，延吉，中国。
五
    上海交通大学医学院附属上海总医院消化内科，上海。
6
    复旦大学附属中山医院消化内科，上海
7
    首都医科大学附属北京天坛医院消化系，北京
8
    北京大学人民医院肝病研究所，中国北京。
9
    河北医科大学第三医院中西医结合肝病科，河北石家庄
10
    首都医科大学附属北京地坛医院肝病中心，北京
11
    中国军队医院302军第二肝硬化诊断治疗中心，北京
12
    石家庄市第五医院传染病科，石家庄
13
    中国人民武装警察部队物流大学附属医院肝胆胰脾科，天津
14
    首都医科大学附属北京佑安医院消化内科，肝病科，北京
15
    首都医科大学附属北京佑安医院病理科，北京
16
    中日友好医院病理科，北京，中国。
17
    临床流行病学和循证医学科，国家消化疾病临床研究中心，北京，中国。

抽象

Wisteria floribunda凝集素阳性Mac-2结合蛋白（M2BPGi）已被确定为干扰素α（IFNα）对病毒性肝炎患者反应的预测因子。然而，在IFNα附加疗法期间，血清M2BPGi是否与慢性乙型肝炎（CHB）患者的肝纤维化消退相关仍然是未知的。 CHB患者接受恩替卡韦治疗26周，然后接受恩替卡韦加peglated-IFNα治疗52周。在基线和治疗第78周时进行肝脏活组织检查。根据Ishak标准或Ishak加进行性 - 不确定 - 回归（P-I-R）标准鉴定纤维化的消退。在基线和治疗的每26周测量血清M2BPGi和肝功能测试。本研究共纳入72名CHB患者。在基线和第78周时，血清M2BPGi与纤维化和坏死性炎症相关。如果使用Ishak标准作为参考，则仅第26周第52周时M2BPGi的百分比变化（Δ％M2BPGi26w-52W）与治疗时的纤维化消退独立相关。第78周，用于预测纤维化消退的Δ％M2BPGi26w-52W的ROC曲线下面积（AUROC）为0.705。至于Ishak加P-I-R标准，纤维化消退预测模型的AUROC（0.896 * M2BPGi52W + 0.363 *坏死性炎症评分0w + 2.051 * Ishak评分0w-4.489）为0.888。这些数据表明血清M2BPGi的动态变化与CHB患者IFNα附加疗法的纤维化消退相关。本文受版权保护。版权所有。

本文受版权保护。版权所有。
关键词：

慢性乙型肝炎; M2BPGi;干扰素α;肝纤维化;回归

结论：
    30905065
DOI：
    10.1002 / jmv.25465